|
 Jinarc, or tolvaptan, was given a green light for the treatment of
autosomal dominant polycystic kidney disease (ADPKD), an hereditary
genetic disease that leads to the development of cysts in the
kidneys.
Recommendations for marketing approval by the European Medicines
Agency's Committee for Medicinal Products for Human Use (CHMP) are
normally endorsed by the European Commission within a couple of
months.
(Reporting by Ben Hirschler; Editing by Tom Bergin)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
